JonesResearch initiated coverage of IN8bio with a Buy rating and $5 price target. The company is developing T cell candidates for hematologic malignancies and solid tumor, the analyst tells investors in a research note. The firm says IN8bio has a differentiated approach compared to the FDA approved CAR T cells. It sees multiple potential inflection points in 2024 for the company and an “improving broader market where stocks with positive data are being rewarded.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on INAB:
- Is INAB a Buy, Before Earnings?
- IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024
- IN8bio announces publication on gamma-delta t cell therapy
- IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology
- IN8bio files to sell 42.7M shares of common stock for holders
